Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits

Autor:	Ann-Mari Svennerholm, G. Castellares, Bruno Vasquez, César Cabezas, Jose L. Sanchez, Rina Meza, Jerald C. Sadoff, R. E. Begue, David N. Taylor, D. M. Watts
Rok vydání:	1994
Předmět:	Adult Male medicine.medical_specialty Adolescent Administration Oral Placebo medicine.disease_cause ABO Blood-Group System law.invention Cholera Double-Blind Method Vibrionaceae law Oral administration Internal medicine Peru medicine Humans Serotyping Vibrio cholerae Immunization Schedule Vaccines Synthetic biology business.industry Incidence Cholera Vaccines General Medicine Middle Aged biology.organism_classification medicine.disease Vaccination Military Personnel Vaccines Inactivated Immunology Recombinant DNA Cholera vaccine business Follow-Up Studies
Zdroj:	The Lancet. 344:1273-1276
ISSN:	0140-6736
Popis:	The cholera epidemic in South America has reinforced the need for safe and effective oral vaccines. In a randomised, double-blind, placebo-controlled efficacy trial among 1563 Peruvian military recruits we have investigated the protective efficacy of an oral inactivated whole-cell/recombinant-B-subunit (WC/rBS) cholera vaccine. Participants were given two oral doses of cholera vaccine or Escherichia coli K12 placebo, with an interval of 7-14 days. 1426 (91%) subjects received the two prescribed doses and were followed up for a mean of 18 weeks (median 21 weeks). After vaccination, Vibrio cholerae O1 El Tor Ogawa was isolated from 17 subjects with diarrhoea. 16 of the cholera cases occurred 2 weeks or longer after the second dose of vaccine (14 placebo recipients, 2 vaccinees). We also detected 14 symptomless infections (11 [7 placebo recipients, 4 vaccinees]) 2 weeks or longer after the second dose. The vaccine had significant protective efficacy against cholera (86% [95% CI 37-97], p0.01) but not against symptomless infection (42% [-96 to 85]). All cholera cases were in people of blood group O, who made up 76% of the study population (p0.01). Two doses of WC/rBS vaccine, given 1 to 2 weeks apart, provide rapid, short-term protection against symptomatic cholera in adult South Americans, who are predominantly of blood group O. Long-term efficacy studies in Peruvian adults and children are under way.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac218654c99e6784298f92b0ac3da5d https://doi.org/10.1016/s0140-6736(94)90755-2 Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.